Employing a bispecific antibody (termed NKAB-ErbB2) which binds to NKG2D and the tumor-associated antigen ErbB2 (HER2), we previously demonstrated that such killer cell engagers not only redirect cytotoxic lymphocytes endogenously expressing NKG2D to ErbB2-positive cancer cells, but also markedly enhance the specific cytotoxicity of NK and T cells carrying an NKG2D-based CAR (NKAR) [27]. The gene discussed is ERBB2; the disease is cancer.